Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients. FE [Internet]. 2016 Mar. 31 [cited 2025 Jul. 23];17(1):7-12. Available from: https://provafe.seedstm.com/index.php/FE/article/view/1225